Cargando…
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
BACKGROUND: It is important to establish the cardiovascular (CV) safety profile of novel antidiabetic drugs. METHODS: Pooled analyses were performed of 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add-on therapy in patients with type 2 diabetes mellitus (T2DM) as well...
Autores principales: | Iqbal, Nayyar, Parker, Artist, Frederich, Robert, Donovan, Mark, Hirshberg, Boaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918110/ https://www.ncbi.nlm.nih.gov/pubmed/24490835 http://dx.doi.org/10.1186/1475-2840-13-33 |
Ejemplares similares
-
Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016) -
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017) -
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012) -
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013) -
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
por: Frederich, Robert, et al.
Publicado: (2012)